<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>For more than 2,000Â years, <z:chebi fb="107" ids="27563">arsenic</z:chebi> and its derivatives have shown medical utility </plain></SENT>
<SENT sid="1" pm="."><plain>Owing to the toxicities and potential <z:e sem="disease" ids="C0858970" disease_type="Neoplastic Process" abbrv="">carcinogenicity</z:e> of arsenicals, their popularity has fluctuated </plain></SENT>
<SENT sid="2" pm="."><plain>The exact mechanism of action of therapeutic <z:chebi fb="107" ids="27563">arsenic</z:chebi> is not well characterized but likely to involve <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, generation of reactive oxygen species, inhibition of intracellular transduction pathways, and cell functions </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="30621">Arsenic trioxide</z:chebi> has received approval for use in patients with relapsed <z:hpo ids='HP_0004836'>acute promyelocytic leukemia</z:hpo> for remission induction </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="107" ids="27563">Arsenic</z:chebi> has additionally shown activity in a range of <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e>, <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo>, and in <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>The following is a review of the history of <z:chebi fb="107" ids="27563">arsenic</z:chebi>, its cellular metabolism, pharmacology, genetic basis of disposition, associated toxicities, and clinical efficacy </plain></SENT>
</text></document>